End Stage Renal Disease. Chronic kidney disease
Conditions
Interventions
Intervention 1: Control group: In the complete intravenous anesthetic group, for induction, Etomidate 3.0 µg/kg is used. For maintenance of anesthesia, Etomidate 100 µg/kg for the first 10 minutes aft
Sponsors
Vice chancellor for research, Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
30 Years to 70 Years
Inclusion criteria
Inclusion criteria: Age between 30 to 70 years ASA class III and IV
Exclusion criteria
Exclusion criteria: Complications during or after laparoscopic surgery
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Systolic blood pressure. Timepoint: First visit the operating room, after the induction, after intubation, before the gas injection into the abdominal cavity, after the injection of the gas into the abdominal cavity and then in the recovery room. Method of measurement: Noninvasive blood pressure monitor.;Diastolic blood pressure. Timepoint: First visit the operating room, after the induction, after intubation, before the gas injection into the abdominal cavity, after the injection of the gas into the abdominal cavity and then in the recovery room. Method of measurement: Noninvasive blood pressure monitor.;Mean arterial blood pressure. Timepoint: First visit the operating room, after the induction, after intubation, before the gas injection into the abdominal cavity, after the injection of the gas into the abdominal cavity and then in the recovery room. Method of measurement: Noninvasive blood pressure monitor. | — |
Secondary
| Measure | Time frame |
|---|---|
| Heart rate per minute. Timepoint: First visit the operating room, after the induction, after intubation, before the gas injection into the abdominal cavity, after the injection of the gas into the abdominal cavity and then in the recovery room. Method of measurement: Monitor. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactRazieh Erfani
Tehran University of Medical Sciences
Outcome results
None listed